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Abstract 
 
One of the major tenets in breast cancer research is that early detection is vital for patient 
survival by increasing treatment options. To that end, we have previously used a novel 
unsupervised approach to identify a set of genes that predict prognosis of breast cancer 
patients. The predictive genes were selected in a well-defined cell culture model of non-
malignant human mammary epithelial cell morphogenesis. Predictive genes were down-
regulated during breast epithelial cell acinar formation and cell cycle arrest, using a three 
dimensional (3D) tissue culture in laminin-rich extracellular matrix. Here we examine the 
ability of this gene-signature (3D-signature) to predict prognosis in two independent large 
breast cancer microarray datasets having 286 samples in one and 122 samples in the 
other. Our results show that the 3D signature accurately predicts prognosis in two 
unrelated patient datasets. We also examine the correlation of individual genes with 
clinical outcome and estrogen receptor (ER) status. Poor prognosis tumors with a shorter 
time to relapse were generally associated with a higher level of expression of individual 
genes. The 3D-signature holds prognostic value for both ER-positive and ER-negative 
breast cancer and includes genes related to cell cycle, cell proliferation, angiogenesis and 
motility. 
 
Introduction 
 
Breast cancer ranks as the second leading cause of death among women with cancer in 
the US. Early detection of breast cancer has a significant impact on patient survival, 
though a portion of patients still relapse and rapidly develop a more aggressive form of 
disease (1). The identification of individuals with a high risk of relapse has become a 
primary focus of cancer research. Key steps are determining which patients will benefit 
from standard care therapies and assessing their chances of disease progression. Accurate 
identification of high-risk genes may not only lead to the identification of groups of high-
risk patients, but also to the discovery of novel therapeutic molecular targets. 
 
Several large studies have been performed to identify predictive signatures in breast 
cancer (2). These signatures have been selected using supervised methods applied to 
training sets of about 50-100 patients, and then confirmed in larger related sets ranging 
from 100-300 patients. It has been observed that the individual genes that comprise 
signatures identified in different studies show surprisingly little overlap. Investigations 
addressing this lack of overlap, have found that predictive signatures are highly 
dependent on the specific set of patients that make up the training set (3). Such disparity 
in signatures is not limited to breast cancer, but also has been found in schizophrenia 
studies. Less well studied is whether a given predictive signature that has been identified 
using a given dataset is also predictive in additional unrelated datasets. 
 
Two predictive signatures for breast cancer identified by microarray analysis have been 
further developed into clinical multi-gene panel tests (4). MammaPrint became the first 
test approved by FDA for predicting breast cancer relapse and is composed of 70 genes. 
Oncotype DX, a prognostic test for ER positive breast cancers, has been commercially 
available since 2004 and is composed of 21 genes. The 70-gene signature was identified 
by analyzing at the large NKI dataset of van de Vijver et al. Unfortunately, subsequent 
analysis found that this signature did not predict outcome as well in an independent 
dataset (5). Several clinical trials are ongoing to test the utility of these prognostic gene-
signature tests (6). 
 
Even though gene signatures so far have been helpful for identifying patients at risk, they 
provide limited information on which genes are relevant to breast cancer biology. It 
follows that all genes included in gene-signatures cannot be key biological players in 
cancer progression. We hypothesize that the ability of a signature to demonstrate 
predictive power across different independent datasets tends to support the conclusion 
that it is composed of key, biologically relevant genes. The development of novel, 
biologically-based gene selection approaches may help to find these genes. We applied 
an unsupervised approach that is not dependent on the composition of a training set. The 
approach is based on a well-studied and biologically relevant model system that mimics 
cellular characteristics of human mammary gland. Since the genes are selected based on a 
biological parameter, they hold promise to represent key biological processes of cancer.  
 
To select a prognosis signature for breast cancer, we used a 3D culture model of non-
malignant human mammary epithelial cells (HMEC) (7). Non-malignant HMEC 
reacquire the ability to form acini-like structures presenting a hollow lumen, basal 
polarity and cell cycle arrest in laminin-rich extracellular matrix 3D culture model. These 
acini structure recapitulate many of the characteristics of luminal cell differentiation in 
the mammary gland (8, 9). Here we describe the predictive power of a small set of 22 
genes that were down-regulated during growth arrest and acini formation of HMEC in 3D 
cultures (3D-signature) in two large, independent breast cancer microarray datasets.  
 
 
Materials and Methods 
 
Dataset sources. The Wang dataset, consisting of the microarray profiles of 286 human 
breast tumors with associated clinical data (10), was obtained from GEO (Series 
GSE2034). The downloaded data were transformed to set measurements less than 25 to 
25, chips and genes were median normalized and median polished. The Sorlie dataset, 
with microarray profiles of 122 human breast tumors and associated clinical data (11), 
was obtained from GEO (Series 4335). Downloaded data were transformed from log base 
2 to linear values, then chips and genes were median-normalized. The van de Vijver 
dataset, with profiles of 295 human breast tumors and associated clinical data (12), was 
obtained from Rosetta Inpharmatics (http://www.rii.com/publications/2002/nejm.html). 
Downloaded data were transformed from log base 2 to linear values; chips and genes 
were median-normalized. Data processing steps were performed using GeneSpring 
software. 
 
Kaplan-Meier curves: For survival analysis with the 3D-signature, patients were stratified 
into two groups using GeneSpring software by hierarchical cluster analysis and the 
expression levels of all 22 genes. Kaplan-Meier survival curves and log-rank statistics for 
these two groups were computed using MedCalc software. For survival analysis of the 22 
individual signature genes, patients were stratified into quartiles for expression of each 
marker and survival curves were computed. Statistical analyses were performed using 
MedCalc software.  
 
 
Results 
 
We have previously used a novel unsupervised approach to identify a set of 22 genes that 
predict prognosis of breast cancer patients (7). This signature included genes that were 
down-regulated during breast epithelial cell acinar formation in 3D cultures in laminin-
rich extracellular matrix (3D lrECM). Identities, Affymetrix IDs, GeneBank accession 
numbers, and biological functions of these genes are tabulated (Supplemental data table 
1).  
 
To further assess the utility of this 3D-signature, we have used two large independent 
breast cancer microarray datasets, both of which include annotated microarray data and 
associated clinical information. The dataset of Wang et al, includes data from 286 breast 
cancer patients while that of Sorlie, et al. (Stanford/Norway) includes data from 122 
patients. Together these datasets represent a total of 408 patients. Numerous differences 
exist between the datasets. Most notably, the patients were selected by different 
institutions using different admittance criteria. Database criteria are tabulated 
(Supplemental data table 2). We have previously shown that the 3D-signature predicted 
prognosis by using the dataset of van de Vijver, et al. (7). We used unsupervised 
hierarchical cluster analysis to group tumors into classes according to their gene 
expression patterns. Here we apply the same approach to the test the 3D-signature’s 
ability to predict prognosis in the two additional datasets. 
 
Probes for all 22 genes were present on the Affymetrix HG-U133A microarrays used by 
Wang, et al. Hierarchical cluster analysis found that the gene expression patterns 
separated the patients in two approximately equally sized clusters. Kaplan-Meier analysis 
was performed using relapse as an endpoint. The two clusters were highly significantly 
associated with prognosis (p=0.000013, Kaplan-Meier) (Figure 1 A, B).  
 
Using the same approach, we also tested the dataset of Sorlie, et al. This dataset used 
Stanford two-color spotted microarrays of varying formats. Data for at least 40% of 
patients was available for 15 of the 22 3D-signature genes. Again, we applied 
hierarchical cluster analysis and found that the tumors were grouped in two 
approximately equally sized clusters. Kaplan-Meier analysis was performed using patient 
death as an endpoint. Results showed that the two clusters were significantly associated 
with prognosis (p=0.045, Kaplan-Meier) (Figure 1 C, D). 
 
The ability of each individual gene of the 3D-signature to predict survival or relapse was 
tested by Kaplan-Meier analysis. For the Wang dataset, the expression levels of nine 
genes were significant predictors of a patient’s time to relapse (Figure 2A). These genes 
included ASPM, AURKA, ACTN1, CEP55, CKS2, DUSP4, EPHA2, TRIP13, and 
VRK1. For each of these genes except DUSP4, poor prognosis tumors with a short time 
to relapse were associated with a higher level of gene expression (>2-fold increase). For 
DUSP4, the pattern was reversed and poor prognosis was associated with a lower level of 
expression (> 2 fold decrease). For the Sorlie dataset, expression levels of seven genes 
were significant predictors of survival time (Figure 2B). These genes included AURKA, 
CDKN3, CEP55, FOXM1, RRM2, TRIP13, and VRK1. For all of these genes, poor 
prognosis was associated with a higher level of gene expression. These Kaplan-Meier p-
values are summarized in Table 1, which also lists our previously determined p-values 
from the van de Vijver dataset for comparison. The results show that 41% (9 of 22), 39% 
(7 of 18), and 68% (13 of 19) of the genes were significant individual predictors in the 
Wang, Sorlie, and van de Vijver datasets, respectively (Table 1).  
 
Table 1 groups the 3D-signature genes by the biological process in which they 
participate. The genes include five categories: cell cycle/mitosis, motility/angiogenesis, 
polyamine biosynthesis, and transcription/replication genes and one gene of unknown 
function. 
 
We have also looked at the ability of the genes to predict prognosis in ER+ and ER- 
subsets of patients. Table 1 lists Kaplan-Meier p-values for ER+ and ER- tumors for all 
three datasets. In the Wang dataset, more of the 3D-signature genes tended to associate 
with prognosis of ER+ tumors (p<0.1) than ER- tumors (Fishers exact test, p=0.034), 
though in the other two datasets, there was no statistical difference in the numbers of 
markers for ER+ and ER- tumors among the 22 genes (Table 1).  
 
A notable finding among the ER related differences was that the genes that tended to 
associate with prognosis in ER+ patients had different molecular functions than the genes 
that tended to associate with prognosis in ER- patients. In particular, significantly more 
cell cycle and transcription genes were prognostic markers for ER+ tumors (Fisher’s 
exact test, p= 0.0047), while prognostic markers of ER- tumors were significantly more 
likely to have functions related to angiogenesis and metastasis (Fisher’s exact test, 
p=0.023). This analysis considered results from all three of the datasets. 
 
To summarize, the genes that tended to associate with prognosis in ER+ tumors (p<0.1 
for at least one of the three datasets) included AURKA, CDKN3, CEP55, DUSP4, 
NCAPG, RRM2, ACTB, EPHA2, FGFBP1, TNFRSF6B, EIF4A1, and VRK1 (Table 1). 
Genes that tended to associate with prognosis in ER- tumors included TUBG1, ACTB, 
FGFBP1, FOXM1, SERPINE2, and TNFRSF6B. Genes that were markers for prognosis 
in both ER+ and ER- tumors included ACTB, FGFBP1, and TNFRSF6B.  
 
We have also tested for an association between expression of the individual 3D-signature 
genes and tumor ER status. (Table 2). We note that expression levels of the majority of 
the 22 genes were significantly associated with ER status. For the Wang, Sorlie, and van 
de Vijver patient datasets, percentages associated with ER status were 91%, 71%, and 
84%, respectively. There was a very strong statistical enrichment for ER status related 
genes among the 3D-signature genes (Fisher’s exact test, p= 3.11e-8, Wang dataset). In 
the Wang dataset, the expression levels of 20 of the 22 signature genes (91%) were 
significantly associated with ER status, while, for the entire set of 22,283 genes, 
expression levels of a total of 7,424 genes (33%) were ER associated (Welch t-test with 
FDR, p<0.05).  
 
The genes that correlated with ER status also correlated with basal/luminal status 
(Fisher’s exact test p=0.011) (data not shown). The majority of the genes were more 
highly expressed in ER- breast cancers than ER+ breast cancers. Two genes (DUSP4 and 
TUBG1) had the reverse pattern and were significantly under-expressed in ER-negative 
tumors (correlation analysis, p<0.05). In the Wang dataset, we found that the highly ER-
associated genes were no more likely to be good prognostic markers than the more poorly 
ER-associated genes (Fishers exact tests, p<0.05) (Table 1). This conclusion applied to 
the subsets of ER+ tumors and ER- tumors, as well as all patients. 
 
 
Discussion 
 
We hypothesized that the changes in gene expression occurring during acini formation of 
non-malignant HMEC in a 3D culture model are opposite from those occurring during 
the development of breast tumors with a poor prognosis. In support of this hypothesis, we 
showed that genes that were expressed at significantly lower levels in organized, growth 
arrested HMEC than in their proliferating counterparts could be used to classify breast 
cancer patients into poor and good prognosis groups (7). The present study provides two 
independent confirmations of a 22 gene prognostic signature (3D-signature) that we 
previously identified using a novel unsupervised strategy. 
 
One of the key criticisms of gene signatures identified using microarray technology is the 
lack of validation across platforms (11, 13). Here we report that the 3D-signature 
predicted prognosis in two large independent datasets (p=0.00001 and 0.045 for datasets 
of Wang et al and Sorlie et al, respectively; Kaplan-Meier analysis). To date, the 3D-
signature has been tested in three large datasets for a total of 703 breast cancer patients. 
There were differences in how well the signature performed between the datasets. 
Prognosis was best for the Wang dataset. Microarrays used for this dataset were identical 
to those of our selection study and included probes for all 22 genes. In contrast, 
microarrays used for the Sorlie dataset included probes for only 15 of the 22 genes, and 
some of these 15 probes could potentially recognize different isoforms of the genes than 
those of the selection study. However, even with these differences with probe 
composition, the 3D-signature accurately predicted prognosis in both datasets. 
 
The 3D-signature includes cell cycle and transcription related genes that predict 
prognosis in ER+ breast cancer patients. This finding is consistent with previous studies 
that show that proliferation and cell cycle genes are the strongest predictor for relapse 
among ER positive patients (14). In several previous studies, a signature enriched in cell 
cycle related genes has been reported to predict poor prognosis of breast cancer, along 
with a second smaller class of genes that includes transcription related genes. Poor 
prognosis in ER+ tumors in particular has been found to be strongly predicted by over 
expression of cell cycle and cell proliferation genes (10, 15-17) . 
 
The 3D-signature also includes angiogenesis and motility genes that are markers for 
prognosis in both ER+ and ER- tumors. Genes in this functional class of breast tumor 
marker genes were also identified in other breast cancer signatures (15, 18), though the 
association of this functional class with ER- tumors has not been noted for gene 
signatures. Markers for ER- tumors have been reported to be significantly less prevalent 
than markers for ER+ tumors (17). Some genes within this functional class predicted 
prognosis for only ER+ tumors, some predicted prognosis for only ER- tumors, and some 
predicted prognosis for both ER+ and ER- tumors. 
 
Since few overlaps have been found among the published breast cancer signatures, it 
appears that many (thousands) of marker genes have predictive ability in different subsets 
of patients. It has been proposed that some genes may have moderate predictive ability in 
many patients, while some may be “master genes” with high predictive ability in as yet 
undefined subsets of patients. When many such genes are used together, a highly accurate 
predictive tool results that is accurate across a wide cross section of breast cancer 
patients. The actual composition of the signature may be less important than the fact the 
each signature is a set of many semi-predictive genes. In contrast to gene signatures 
identified from specific patient sets by supervised methods, our approach is based on a 
well studied and biologically relevant model system that mimics the human mammary 
gland. Hence the 3D-signature holds promise to include “master genes” of key biological 
processes of cancer. 
 
Earlier detection can benefit patient survival and treatment options; however progress is 
still needed in developing therapeutic strategies amenable to early stage disease. A focus 
on the development of novel treatments targeting early disease rather than advanced 
malignant carcinoma seems to be a natural next step. The identification of key regulatory 
pathways that maintain the self-limited proliferation of non-malignant cells in 3D 
cultures may direct us to novel molecular targets for earlier cancer therapy. 
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Figure Legends 
 
Figure 1. The 22 gene 3D signature predicts survival in the microarray datasets of 
Wang, et al., and Sorlie, et al. The 22 gene signature and unsupervised hierarchical 
clustering grouped breast cancer patients to accurately reflect overall relapse or survival 
when analyzed by the method of Kaplan and Meier. A. Hierarchical cluster analysis of 
the dataset of Wang, et al. The pattern of expression of the 22 genes selected by the 3D 
assay are shown for the 286 breast cancer patients of Wang et al. Genes and samples 
were organized by using hierarchical clustering. The two major clusters in the sample 
dimension (red cluster and yellow cluster), were found by using survival analysis to 
distinguish between good and poor prognosis patients (p < 0.0001).  B. Kaplan-Meier 
curves for the red and yellow clusters of the hierarchical diagram of panel A. The 
endpoint recorded for this dataset was relapse, measured in months. C. Hierarchical 
cluster analysis of Sorlie, et al. dataset. The pattern of expression of the 15 of 22 genes 
with probes on the Stanford microarrays and with data available for at least 40% of 
patients are shown for the 121 breast cancer patients reported by Sorlie et al. Expression 
was  organized by hierarchical clustering. The two major clusters in the sample 
dimension (red cluster and yellow cluster), were found by using survival analysis to 
distinguish between good and poor prognosis patients (p = 0.00447).  D. Kaplan-Meier 
curves for the red and yellow clusters of the hierarchical diagram of panel C. The 
endpoint recorded for this dataset was death, measured in months. 
 
Figure 2. Kaplan-Meier curves of the individual genes that accurately predicted 
patient prognosis (p<0.05).  A. Results for individual genes in the dataset of Wang, et 
al. using patient relapse as the endpoint. B. Results for individual genes in the dataset of 
Sorlie, et al. using patient survival as the endpoint. 
 
Supplemental Figure 1. Kaplan-Meier curves of the individual genes that did not 
accurately predict patient prognosis (p>0.05).  A. Results for individual genes in the 
dataset of Wang, et al. using patient relapse as the endpoint. B. Results for individual 
genes in the dataset of Sorlie, et al. using patient survival as the endpoint. 
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Table 1.  Kaplan-Meier p-values for the 22 individual genes in the Wang, Sorlie, and 
van de Vijver patient datasets 
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* Data previously reported (Fournier et al., Cancer Research 2007).
ns = not significant;  -   = no data; bold/underlined = p<0.05. 
 
 
 
 
 
Table 2. ER association of the 22 individual genes in patient datasets from Wang, 
Sorlie, and van de Vijver (Welch t-test p values with false positive multigene 
correction). 
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ns = not significant;  -   = no data 
B. Sorlie dataset genes with Kaplan p > 0.05
p = 0.0505
ACTB
p = 0.186
p = 0.544
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A.  Wang dataset genes with Kaplan p > 0.05
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Interquartile range
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p = 0.962
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p = 0.775
ACTN1
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p = 0.415
EPHA2
p = 0.146
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p = 0.552
DUSP4
p = 0.452
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p = 0.353
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p = 0.146
TNFRSF6B
p = 0.805
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p = 0.453
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transcription/replicationvaccinia related kinase 1NM_003600204092_s_at-VRK1
transcription/replicationthyroid hormone receptor interactor 13NM_004237204033_at-TRIP13
transcription/replicationeukaryotic translation initiation factor 4A, isoform 1NM_001070201714_at-EIF4A1
polyamine biosynthesisornithine decarboxylase 1NM_003823206467_x_at-ODC1
motility / angiogenesisserpin peptidase inhib 2 (nexin)AL541302212190_at-SERPINE2
motility / angiogenesisforkhead box M1NM_003384203856_at-FOXM1
motility / angiogenesisheparin-binding growth factor binding proteinBC003576208637_x_atHBP17FGFBP1
motility / angiogenesisEPH receptor A2BC001886209773_s_at-EPHA2
motility / angiogenesisactin, betaNM_021953202580_x_at-ACTB
motility / angiogenesisactinin, alpha 1NM_022346218663_at-ACTN1
cell cycle/mitosisasp (abnormal spindle) homolog, microcephaly assocNM_018123219918_s_atFLJ10517ASPM
cell cycle/mitosisaurora kinase ANM_018131218542_atSTK6AURKA
cell cycle/mitosiscyclin-dep kinase inhib 3 (CDK2-assoc dual spec phos)NM_023925218456_at-CDKN3
cell cycle/mitosiscentrosomal protein 55kDaAF213033209714_s_atFLJ10540CEP55
cell cycle/mitosisCDC28 protein kinase regulatory subunit 2NM_001827204170_s_at-CKS2
cell cycle/mitosisdual specificity phosphatase 4NM_001394204014_at-DUSP4
cell cycle/mitosischromosome condensation protein GU79273214805_atHCAP-GNCAPG
cell cycle/mitosisribonucleotide reductase M2 polypeptideNM_004431203499_at-RRM2
cell cycle/mitosistubulin, gamma 1NM_005130205014_at-TUBG1
unknown functionC1q domain containing 1NM_002539200790_atCAPRIN2C1QDC1
motility / angiogenesiszwilch, kinetochore associated, homologNM_017975218349_s_atFLJ10036ZWILCH
motility / angiogenesistumor necrosis factor receptor superfamily, 6b, decoyNM_001101200801_x_at
TNFRSF6B
/RTEL1
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Supplemental Table 1. List of 22 genes in prognostic signature of Fournier et al. 2006
Supplemental Table 2. Comparison of microarray datasets.
DeathHistology subtypes 
included 4 normal breast, 
2 DCIS, 100 invasive 
ductal carcinoma, 3 
fibroadenoma, 8 lobular 
carcinoma, and 1 each of 
mucinous, papillary, 
pleomorphic, and 
undifferentiated 
carcinomas
12210-198 different 
platforms 
ranging from 
9,200 to 
54,000 
features
Fluorescent 
arrays made at 
Stanford 
University
PNAS 2003; 
100:8418-23
Sorlie
RelapseLymph-node negative 
patients with no systemic 
therapy
2862223,000Affymetrix HG-
U133A
Lancet 2005; 
365:671–79
Wang
DeathStage I or II invasive 
carcinoma patients less 
than 52 years of age
2951925,000Fluorescent 
array made by 
Rosetta 
Inpharmatics
NEJM 2002; 
347:1999-
2009
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